GeneDx Holdings Corp.

Rule 10b5-1 Plan Adoptions and Modifications

None.

Supplemental Disclosure to our Annual Report on Form 10-K for the year ended December 31, 2025

The following updates Part I, Item 1.“Business—Intellectual Property—Patents” in our 2025 Form 10-K:

Patents

Our patent protection strategy has focused on seeking protection for certain of our non-gene specific technology and our specific biomarkers. In this regard, as of September 30, 2026, we have one issued U.S. utility patent, one issued U.S. design patent, two granted European patents, one granted Canadian patent, sixteen pending U.S. non-provisional utility patent applications, three pending U.S. provisional patent applications, and four pending international PCT patent applications. The issued U.S. utility patent relates to therapeutic treatment for subjects having certain polymorphic markers associated with specific human leukocyte antigen alleles. The issued U.S. design patent relates to a display screen with a graphical user interface. One granted European patent relates to a variant annotation, analysis and selection tool and has been validated in France, Germany, Ireland, Switzerland and the United Kingdom. The other granted European patent relates to genome analysis and has been validated in France, Germany, Italy, the Netherlands, Spain and the United Kingdom. The granted Canadian patent also relates to genome analysis.

The pending utility patent applications include an international PCT patent application and a U.S. patent application related to performing phenotypic fit analysis; an international PCT patent application and two U.S. patent applications related to processing genetic variations and phenotypes; an international PCT patent application and a U.S. patent application related to modeling inference of mutation impact; a U.S. patent application related to identifying cancer diagnoses and diagnosis dates from electronic health records using machine learning; a U.S. patent application related to predicting cancer homologous recombination pathway deficiency and determining treatment response; four U.S. patent applications related to therapeutic treatment for subjects having certain polymorphic markers associated with specific human leukocyte antigen alleles, three of which have been issued on October 20, 2026; two U.S. patent applications related to analyzing phenotype-causing genomic variants; two U.S. patent applications related to prioritizing phenotype-causing genomic variants in combination with biomedical ontologies; two U.S. patent applications related to prioritizing phenotype-causing genomic variants in combination with clinical information; and an international PCT patent application related to ultra-long context genomic language modeling. Two of the pending U.S. provisional patent applications relate to variant analysis, and one relates to multilayer genomic processing.

Our issued patents will begin expiring in 2029. If patents are issued from the currently pending applications, the earliest patents will begin expiring in the early 2030s, subject to potential extensions of the patent term that will be calculated based on the length of the patent examination process. The claim scope of any potentially issued patents stemming from the present applications may be narrower than included in the initial filings due to any amendments that may arise throughout their prosecution.

Recent Accounting Pronouncements

Additional information on recent accounting pronouncements can be found in Note 2, “Summary of Significant Accounting Policies” to our consolidated financial statements included within our 2025 Form 10-K, and Note 2, “Summary of Significant Accounting Policies” to our condensed consolidated financial statements included in this Quarterly Report.